NO20082098L - Formuleringer av AICA-ribosid - Google Patents

Formuleringer av AICA-ribosid

Info

Publication number
NO20082098L
NO20082098L NO20082098A NO20082098A NO20082098L NO 20082098 L NO20082098 L NO 20082098L NO 20082098 A NO20082098 A NO 20082098A NO 20082098 A NO20082098 A NO 20082098A NO 20082098 L NO20082098 L NO 20082098L
Authority
NO
Norway
Prior art keywords
formulations
kits
aica riboside
condition
patient
Prior art date
Application number
NO20082098A
Other languages
English (en)
Norwegian (no)
Inventor
Dennis Mangano
Ricard R Stover
Ross Dixon
Sharon Wu
Marvin J Sack
Original Assignee
Pericor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pericor Therapeutics Inc filed Critical Pericor Therapeutics Inc
Publication of NO20082098L publication Critical patent/NO20082098L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
NO20082098A 2005-10-07 2008-05-06 Formuleringer av AICA-ribosid NO20082098L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/246,763 US20070082859A1 (en) 2005-10-07 2005-10-07 Formulations of AICA riboside
PCT/US2006/038692 WO2007044357A2 (fr) 2005-10-07 2006-10-03 Preparations d'aica-riboside

Publications (1)

Publication Number Publication Date
NO20082098L true NO20082098L (no) 2008-06-30

Family

ID=35735993

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082098A NO20082098L (no) 2005-10-07 2008-05-06 Formuleringer av AICA-ribosid

Country Status (12)

Country Link
US (1) US20070082859A1 (fr)
EP (1) EP1933819A4 (fr)
JP (1) JP2009511476A (fr)
KR (1) KR20080059632A (fr)
CN (1) CN101277685A (fr)
AU (1) AU2006302530A1 (fr)
BR (1) BRPI0616913A2 (fr)
CA (1) CA2624073A1 (fr)
GB (1) GB2430882A (fr)
NO (1) NO20082098L (fr)
WO (1) WO2007044357A2 (fr)
ZA (1) ZA200802646B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070121026A (ko) * 2005-03-28 2007-12-26 페리코르 테라퓨틱스, 인크. 환자에 있어서 부정적 영향을 방지하거나 감소시키기 위한방법, 조성물 및 제제
TWI647209B (zh) 2007-08-08 2019-01-11 環球展覽公司 磷光發光二極體內之單聯伸三苯發色團
US8646243B2 (en) * 2007-10-04 2014-02-11 Medical Instill Technologies, Inc. Apparatus for formulating and aseptically filling liquid products
CA2739463C (fr) * 2008-10-03 2018-07-03 Pericor Therapeutics, Inc. Procedes et compositions pour le traitement de l'insuffisance cardiaque aigue
US20120258926A1 (en) * 2009-12-15 2012-10-11 Valentyn Antochshuk Formulations of acadesine
US10780228B2 (en) 2012-05-07 2020-09-22 Medline Industries, Inc. Prefilled container systems
EP3089748A4 (fr) * 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Traitement de la néovascularisation oculaire
US20170349313A1 (en) * 2016-06-01 2017-12-07 Centurion Medical Products Corporation Methods for manufacturing non-glass prefilled syringes
CN110770720B (zh) * 2017-08-31 2023-11-07 深圳市欢太科技有限公司 资源搜索方法及相关产品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271386A (en) * 1964-06-01 1966-09-06 Pfizer & Co C 5-amino-4-imidazolecarboxamide riboside recovery process
JPS4944349B1 (fr) * 1967-06-16 1974-11-27
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AU529815B2 (en) * 1981-05-15 1983-06-23 Fisons Plc Optically active imidazole derivatives
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5118601A (en) * 1986-03-27 1992-06-02 The Regents Of The University Of California Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
US5200525A (en) * 1989-01-24 1993-04-06 Gensia Pharmaceuticals Anti-seizure compounds
US5187162A (en) * 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
CA2151588C (fr) * 1992-12-16 2002-03-19 Michael D. Varney 5-thiapyrimidinone et 5-selenopyrimidinone substitues ayant des proprietes antiproliferatives
IL108524A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5366960A (en) * 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
EP1492564A2 (fr) * 2001-10-31 2005-01-05 Université Libre de Bruxelles Agonistes de kinase amp ou promedicaments d'adenosine en tant qu'agents immunostimulants
ES2192495B1 (es) * 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
EP1711197A4 (fr) * 2003-12-23 2008-11-05 Musc Found For Res Dev Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
KR20070121026A (ko) * 2005-03-28 2007-12-26 페리코르 테라퓨틱스, 인크. 환자에 있어서 부정적 영향을 방지하거나 감소시키기 위한방법, 조성물 및 제제

Also Published As

Publication number Publication date
WO2007044357A2 (fr) 2007-04-19
JP2009511476A (ja) 2009-03-19
EP1933819A2 (fr) 2008-06-25
CA2624073A1 (fr) 2007-04-19
GB2430882A (en) 2007-04-11
AU2006302530A1 (en) 2007-04-19
WO2007044357A3 (fr) 2007-09-27
GB0525300D0 (en) 2006-01-18
ZA200802646B (en) 2009-09-30
KR20080059632A (ko) 2008-06-30
EP1933819A4 (fr) 2009-07-22
BRPI0616913A2 (pt) 2016-08-23
CN101277685A (zh) 2008-10-01
US20070082859A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
NO20082098L (no) Formuleringer av AICA-ribosid
SG162788A1 (en) Self-buffering protein formulations
MEP25008A (en) Topical methadone compositions and methods for using the same
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
LTC2201840I2 (lt) Brutono tirozinkinazės inhibitoriai
NO20075046L (no) Gastroresistente farmasoytiske formuleringer inneholdende rifaximin
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
WO2005055944A3 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
ATE366547T1 (de) Implantat zur okklusion eines körperkanals
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BRPI0615265A8 (pt) composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
NO20061502L (no) Fremgangsmate for behandling av endometriose
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BRPI0414215A (pt) tienopirazóis
WO2006116185A3 (fr) Procedes destines au traitement de myelomes multiples
ATE548043T1 (de) Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
EP1370697A4 (fr) Medicaments a base de peroxyredoxine pour le traitement d'infections par le vih-1, et leurs methodes d'utilisation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application